Seasonal Affective Disorder Therapeutics Market: Rising Adoption of Bright Light Therapy to Drive Growth: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

Seasonal Affective Disorder Therapeutics Market: Rising Adoption of Bright Light Therapy to Drive Growth: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

Physicians are Increasingly Recommending Bright Light Therapy

It has been noted that physicians across the globe are increasingly recommending Bright Light Therapy (BLT) as a prophylactic measure for Depression and Seasonal Affective Disorder Therapeutics. BLT provides a robust, rapid and completely anti-depressant effect. The light therapy onset should be typically within four days of Seasonal Affective Disorder. Monitoring should be done on a phase resetting basis on timed effects of introduction of bright light.

The dosage of light therapy can be titrated against side effects and patients can easily avoid drug-drug interactions. Use of bright light therapy in self-reporting population and sub-syndromal disease impacted population is a clear way to boost revenue visibility for Seasonal Affective Disorder Therapeutics market over the forecast period.

External Factors Impact Treatment Decisiveness Among Physicians

There are several external factors that impact treatment decisiveness among physicians for seasonal affective disorder. These include patient expectations, disease history and stability, risk/benefit ratio and lastly, lack of evidence. Apart from willingness of patients, there are six other traits that impact the Seasonal Affective Disorder Therapeutics uptake and adherence rates among patients suffering from seasonal affective disorder.

These include awareness about disease and available preventive treatment options, prognostic experience with treatment in acute phase of the disease, acceptability of suggestive medical interventions and absolute willingness to take responsibility for oneself after the medical intervention has begun. Culmination of all above mentioned factors actually impacts the Seasonal Affective Disorder Therapeutics decisiveness among physicians.

This trend is likely to impact the revenue generation ability of available options for Seasonal Affective Disorder Therapeutics, positively as adherence in long term is directly proportional to increased patient awareness and acceptance.

Improper Treatment Management Can Backfire and Lead to Serious Side Effects

Experts have noted that improper Seasonal Affective Disorder Therapeutics can have serious side effects and lead to a significant dip in adoption rates of Seasonal Affective Disorder Therapeutics. To stop these side effects of Seasonal Affective Disorder Therapeutics, the dosage should be reduced, stopped and re-challenged after two to three days.

In this regard, it’s worth noting that adjunctive light therapy should begin with a dose titration of 7,000 lux, 4000 K blue enriched broad spectrum white light for 15 minutes per day at midday around 2.30pm in the noon. Then 15 minutes should be added each subsequent week till the dosage reaches a range of 45-60 minutes per day. Average time to response and remission varies between four and six weeks normally. Continuous patient-physician engagement leads to better Seasonal Affective Disorder Therapeutics.

Availability of Broad Options for Treatment

A wide range of options are available in the market for Seasonal Affective Disorder Therapeutics. Both drugs and devices are available in the market for Seasonal Affective Disorder Therapeutics. Light therapy is used as the first line of therapy for the Seasonal Affective Disorder Therapeutics. A wide range of devices, such as light boxes, desk lamps, dawn stimulators and sun visors are available in the market as light therapy for Seasonal Affective Disorder Therapeutics.

Both branded and generic drugs for Seasonal Affective Disorder Therapeutics are available in developed and developing economies. Citalopram and Buproban are commonly used drugs for the Seasonal Affective Disorder Therapeutics. Also, a wide number of generic options for Citalopram and Buproban are available in the market for Seasonal Affective Disorder Therapeutics. Therefore, easy availability of broad options for Seasonal Affective Disorder Therapeutics will boost the revenue growth of the market. 

Competitive Landscape

The competition section of the Seasonal Affective Disorder Therapeutics market report features the profiles of key players in the Seasonal Affective Disorder Therapeutics market based on their product offerings, market shares, marketing approach and differential strategies.

Some of the key players profiled in the Seasonal Affective Disorder Therapeutics market report include Allergan plc., Eli Lily Company, GlaxoSmithKline plc,  Pfizer Inc., Teva Pharmaceuticals Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche AG, Mylan N.V., Sanofi AG, Novartis AG, Janssen Pharmaceuticals, Inc., The Sunbox Company,  Verilux, Inc., Carex Health, Northern Light Technologies, Beurer GmbH and Koninklijke Philips N.V.

Definition

Seasonal affective disorder (SAD) is a category of depression that emerges in particular seasons of the year. Most people notice SAD symptoms starting in the fall and these symptoms increase during the winter months, but a few people also experience the spring and summer version. The symptoms of Seasonal affective disorder (SAD) includes heaviness in arms and legs, frequent oversleeping, cravings for carbohydrates, weight gain and others.

About the Report

FMI has conducted a research study on the Seasonal Affective Disorder Therapeutics market for the forecast period 2018 to 2028. The Seasonal Affective Disorder Therapeutics market report offers a comprehensive evaluation of the business opportunities prevailing in the Seasonal Affective Disorder Therapeutics market, along with insights on pipeline assessment of depression drugs used for SAD, key regulations and reimbursement scenario.

The report on the Seasonal Affective Disorder Therapeutics market also elaborates on the macro-economic factors influencing the dynamics in the Seasonal Affective Disorder Therapeutics market.

Additional Questions Answered

Some of the additional questions addressed in this report on Seasonal Affective Disorder Therapeutics market are:

  • What is the revenue potential of drugs and devices used for Seasonal Affective Disorder Therapeutics across regions of North America and Europe?
  • Who are the key competitors in the Seasonal Affective Disorder Therapeutics market and what are their product portfolios and growth strategies?
  • What are the major factors influencing the growth of the Seasonal Affective Disorder Therapeutics market?
  • Which trends are being followed by the leading manufacturers to retain their market share?
  • What is the prevalence and treatment-seeking rate for Seasonal Affective Disorder Therapeutics in the top countries?

Key Segment

based on treatment type

  • light boxes
  • dawn stimulators
  • desk lamps
  • sun visors

based on disorder type

  • SSRIs
  • SNRIs
  • NDRIs
  • TCAs
  • MOAIs

based on Distribution channel

  • institutional sales
  • retail sales

based on regions

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania and MEA

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports

Recommendations

Seasonal Affective Disorder Therapeutics Market